Sanofi’s Taxotere Gets Priority Review For Head And Neck Cancer Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval would place the taxane in more direct competition with ImClone/Bristol’s Erbitux.
You may also be interested in...
Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Approval marks the eighth indication for docetaxel in five different tumor types.
Sanofi-Aventis’ Taxotere Adds New Head And Neck Cancer Indication
Approval marks the eighth indication for docetaxel in five different tumor types.
Erbitux Shows Survival Benefit With Chemo In First-Line Metastatic Head & Neck Cancer
ImClone/Bristol will discuss potential for submitting an sBLA for the indication with FDA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: